Agenus Inc. (NASDAQ:AGEN) VP Christine M. Klaskin sold 5,610 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $3.46, for a total value of $19,410.60. Following the transaction, the vice president now owns 69,943 shares of the company’s stock, valued at approximately $242,002.78. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of Agenus Inc. (AGEN) traded up $0.01 during mid-day trading on Thursday, reaching $3.52. The company’s stock had a trading volume of 782,618 shares, compared to its average volume of 1,184,884. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39. Agenus Inc. has a one year low of $3.20 and a one year high of $5.45.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.37). The business had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. The company’s revenue was down 24.4% on a year-over-year basis. equities analysts expect that Agenus Inc. will post -1.19 EPS for the current year.

AGEN has been the subject of a number of analyst reports. Zacks Investment Research upgraded Agenus from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Wednesday, October 25th. ValuEngine upgraded Agenus from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Finally, BidaskClub lowered Agenus from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $5.81.

Hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new stake in shares of Agenus in the third quarter valued at $134,000. OxFORD Asset Management LLP acquired a new stake in shares of Agenus in the second quarter valued at $141,000. Voya Investment Management LLC lifted its holdings in shares of Agenus by 18.5% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 6,381 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of Agenus in the second quarter valued at $207,000. Finally, Metropolitan Life Insurance Co. NY lifted its holdings in shares of Agenus by 12.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock valued at $211,000 after buying an additional 6,101 shares during the period. Institutional investors own 37.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Christine M. Klaskin Sells 5,610 Shares of Agenus Inc. (AGEN) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/14/christine-m-klaskin-sells-5610-shares-of-agenus-inc-agen-stock.html.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.